Michel Delforge
- Hematology top 0.2%
- Multiple Myeloma Research and Treatments 95
- Acute Myeloid Leukemia Research 15
- Genetics top 1%
- Chronic Lymphocytic Leukemia Research 12
- Oncology top 2%
- Cancer Treatment and Pharmacology 30
- CAR-T cell therapy research 15
- Peptidase Inhibition and Analysis 12
- Immunology top 5%
- Molecular Biology top 5%
- Protein Degradation and Inhibitors 38
- Amyloidosis: Diagnosis, Treatment, Outcomes 14
- Co-authors
- Meletios Α. DimopoulosJesús F. San MiguelMichèle CavoBob AsselberghPeter VandenabeeleEllen WirawanQuinten RemijsenJean Willems
- Cited by
- HematologyGeneticsOncology
- Partner nations
- BelgiumUnited StatesSpain
In The Last Decade
Michel Delforge
147 papers receiving 4.3k citations
Hit Papers
Peers
Comparison fields: 5 of 120
- Hematology 2.6k
- Genetics 646
- Oncology 1.6k
- Immunology 846
- Molecular Biology 2.1k
Countries citing papers authored by Michel Delforge
This map shows the geographic impact of Michel Delforge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michel Delforge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michel Delforge more than expected).
Fields of papers citing papers by Michel Delforge
This network shows the impact of papers produced by Michel Delforge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michel Delforge. The network helps show where Michel Delforge may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Michel Delforge, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | 2024 | 2 | |
| 3 | 2024 | 7 | |
| 4 | 2024 | 9 | |
| 5 | 2024 | 0 | |
| 6 | 2024 | 8 | |
| 7 | 2024 | 1 | |
| 8 | 2024 | 1 | |
| 9 | 2023 | 16 | |
| 10 | Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients | 2022 | 5 |
| 11 | 2021 | 7 | |
| 12 | 2020 | 2 | |
| 13 | 2019 | 24 | |
| 14 | 2019 | 58 | |
| 15 | 2018 | 78 | |
| 16 | 2012 | 4 | |
| 17 | Apoptosis levels of CD34+cells after induced DNA damage: Measurement of DNA fragmentation in different annexin V-affinity fractions of sorted CD34+cells using the DNA diffusion assay and comet assay | 2007 | 1 |
| 18 | Refining the classification of low risk MDS: Retrospective analysis of cytomorphological and histological variables in 138 patients | 2003 | 2 |
| 19 | The immunophenotype and function of dendritic cells in myelodysplastic syndromes | 2002 | 1 |
| 20 | Are AClonal@ X-chromosome inactivation patterns of T cells in MDS dependent on disease duration ? Evaluation of 117 patients with MDS | 2001 | 1 |
About Michel Delforge
Michel Delforge is a scholar working on Hematology, Oncology, Genetics, Molecular Biology and Immunology, having authored 150 papers that have together received 4.4k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (95 papers), Protein Degradation and Inhibitors (38 papers), Cancer Treatment and Pharmacology (30 papers), Acute Myeloid Leukemia Research (15 papers), CAR-T cell therapy research (15 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (14 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Peptidase Inhibition and Analysis (12 papers). The work is most often cited by research in Hematology (2.6k citations), Genetics (646 citations), Oncology (1.6k citations), Immunology (846 citations) and Molecular Biology (2.1k citations). Michel Delforge has collaborated with scholars based in Belgium, United States and Spain. Frequent co-authors include Meletios Α. Dimopoulos, Jesús F. San Miguel, Michèle Cavo, Bob Asselbergh, Peter Vandenabeele, Ellen Wirawan, Quinten Remijsen, Jean Willems, Sam Noppen and Eef Parthoens. Their work appears in journals such as Blood, Journal of Clinical Oncology, Leukemia, British Journal of Haematology and Haematologica.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.